Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
A team of Columbia scientists is examining patient samples and experimenting with organoids to understand why colon cancer is on the rise in people under 50.
From Staten Island to Northern Manhattan, Columbia's Cancer Center works side by side with the communities it serves, putting research into action through programs that address critical needs.
In tests with mice, inhalable exosomes created by Columbia biomedical engineers successfully delivered cancer treatment to the lungs and suppressed tumor growth without toxic side effects.
Some cancer cells escape their tumors and stay dormant in other parts of the body before seeding metastases. Columbia researchers have identified a switch that could put the cells back to sleep.
A combination of a diabetes drug and a PI3K inhibitor may have potential in preventing melanoma from spreading to the liver, according to a study from Columbia cancer researchers.
A study from Columbia cancer researchers suggests drugs targeting the SMARCAL1 protein could strike a double blow against many cancers and make immunotherapy even more effective.
A working group of international experts, including Columbia's Mary Beth Terry, evaluated the current evidence around limiting or stopping alcohol use and lowering the risk of certain types of cancer.
A clinical trial based on discoveries made by researchers in Columbia’s Pancreas Center is showing promising results and is now expanding to include more patients.
A new study is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development of new treatments.